{"id":59731,"date":"2024-07-22T19:05:23","date_gmt":"2024-07-22T17:05:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/"},"modified":"2024-07-22T19:05:23","modified_gmt":"2024-07-22T17:05:23","slug":"lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/","title":{"rendered":"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan"},"content":{"rendered":"
\n

\nBeasley Allen, Levin Papantonio, and coalition of law firms cite <\/i>misleading efforts to secure approval<\/i><\/p>\n

TRENTON, N.J.–(BUSINESS WIRE)–Thousands of individuals who are being told they may be eligible for quick and significant compensation from a proposed $6.5 billion bankruptcy settlement offered by Johnson & Johnson (NYSE:JNJ) are being misled, according to other attorneys who represent ovarian cancer victims.<\/p>\n

\n\u201cWe believe there is an ongoing effort to attract approvals for J&J\u2019s third attempt at bankruptcy from those without a documented and diagnosed claim of ovarian cancer,\u201d says Andy Birchfield<\/a> of the Beasley Allen<\/a> Law Firm.<\/p>\n

\n\u201cWhile individuals may have a gynecological illness or other medical condition, we don\u2019t believe those votes should be used as part of a bankruptcy effort to coercively resolve ovarian cancer claims linked to Johnson & Johnson\u2019s baby powder. Other claims may involve a serious condition, but we fear they are only being used to stuff the ballot box.\u201d<\/p>\n

\nUnder a pre-packaged bankruptcy, 75% of the plaintiffs or creditors must approve the proposed plan before it can be filed. Two previous bankruptcy plans filed by J&J and its affiliates have been denied by the courts because they were filed in bad faith.<\/p>\n

\nBirchfield and attorneys from more than 50 law firms opposing J&J\u2019s voting scheme believe that the solicitation for \u201cyes\u201d votes is being used to create a false basis for a bankruptcy that could reduce payments to their clients, who have incurred individual losses and expenses of $500,000 or more in battling the disease.<\/p>\n

\n\u201cJ&J is aware that the thousands of fantasy cases they are submitting to bankruptcy make it almost impossible for actual injured clients to recover,\u201d says Mike Papantonio<\/a> of Levin Papantonio<\/a>.<\/p>\n

\nEmploying an at-times desperate strategy, J&J has attacked its former customers who have filed lawsuits, labeling them \u201cnameless\u201d and \u201cfaceless.\u201d \u201cThis is a profoundly insulting statement to make about the very customers who trusted the company,\u201d says Birchfield. \u201cThousands of women \u2013 mothers, sisters, daughters, aunts & cousins, whose lives have been upended by ovarian cancer linked to J&J\u2019s talc products.\u201d<\/p>\n

\nVideo: Victims Speak Out<\/b><\/p>\n

\nScores of women have described their pain in videos<\/a> as they have battled ovarian cancer and opposed the bankruptcy plan on principle.<\/p>\n

\n\u201cThese are real people who have suffered solely because of the deceit of Johnson & Johnson,\u201d says Richard Golomb<\/a> of Golomb Legal<\/a>. \u201cUnder J&J\u2019s plan, there is no basis to know how much a client would be paid or when, but it\u2019s logical that accepting an extraordinarily large number of claims would reduce the benefit available to all.<\/p>\n

\n\u201cA few thousand dollars is not justifiable for an individual with a legitimate and longstanding medical diagnosis of ovarian cancer, but that\u2019s what the math of this proposal demonstrates.\u201d<\/p>\n

\nThe deadline for voting to approve or decline the bankruptcy proposal is 5 p.m. ET on July 26, 2024.<\/p>\n

\nAttorneys opposing the J&J plan also note that approval would take away all rights to a jury trial for current and future ovarian cancer victims. Since 2016, juries have awarded collectively more than $5.4 billion in compensatory and punitive damages to ovarian cancer claimants. Although that total has been subsequently reduced by courts at the trial and appellate level, those reductions have not been based on the merits of the underlying cases.<\/p>\n

\n\u201cWe welcome any individuals and their attorneys to file claims, with the required medical records and pathology reports, in the ongoing multidistrict litigation for ovarian cancer cases,\u201d says Michelle Parfitt<\/a>, co-lead counsel of the plaintiffs\u2019 committee over more than 50,000 plaintiffs whose claims were previously consolidated in multidistrict litigation (MDL) in federal court. \u201cThe MDL, and civil courts in general, still provide the most fair and efficient means of trying and resolving these cases, with the first bellwether trial scheduled for December.\u201d<\/p>\n

\n\u201cThose trials have been delayed solely due to J&J\u2019s gamesmanship, desire to avoid trials, and repeated and unsuccessful attempts to claim bankruptcy for a company valued at nearly $400 billion, says Leigh O\u2019Dell<\/a>, co-lead counsel of the plaintiffs\u2019 committee in the MDL litigation. \u201cIt\u2019s a scheme with direct parallels to that attempted by Purdue Pharmaceuticals, which the U.S. Supreme Court recently overturned.\u201d<\/p>\n

Contacts<\/b> <\/p>\n

\nMike Androvett
\n
800-559-4534
\n
mike@androvett.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Beasley Allen, Levin Papantonio, and coalition of law firms cite misleading efforts to secure approval TRENTON, N.J.–(BUSINESS WIRE)–Thousands of individuals who are being told they may be eligible for quick and significant compensation from a proposed $6.5 billion bankruptcy settlement offered by Johnson & Johnson (NYSE:JNJ) are being misled, according to other attorneys who represent … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59731","6":"format-standard","7":"category-industry"},"yoast_head":"\nLawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Beasley Allen, Levin Papantonio, and coalition of law firms cite misleading efforts to secure approval TRENTON, N.J.–(BUSINESS WIRE)–Thousands of individuals who are being told they may be eligible for quick and significant compensation from a proposed $6.5 billion bankruptcy settlement offered by Johnson & Johnson (NYSE:JNJ) are being misled, according to other attorneys who represent ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-22T17:05:23+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan\",\"datePublished\":\"2024-07-22T17:05:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\\\/\"},\"wordCount\":735,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\\\/\",\"name\":\"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2024-07-22T17:05:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/","og_locale":"en_US","og_type":"article","og_title":"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan - Pharma Trend","og_description":"Beasley Allen, Levin Papantonio, and coalition of law firms cite misleading efforts to secure approval TRENTON, N.J.–(BUSINESS WIRE)–Thousands of individuals who are being told they may be eligible for quick and significant compensation from a proposed $6.5 billion bankruptcy settlement offered by Johnson & Johnson (NYSE:JNJ) are being misled, according to other attorneys who represent ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/","og_site_name":"Pharma Trend","article_published_time":"2024-07-22T17:05:23+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan","datePublished":"2024-07-22T17:05:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/"},"wordCount":735,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/","url":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/","name":"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2024-07-22T17:05:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lawyers-for-ovarian-cancer-victims-urge-no-vote-on-jjs-latest-bankruptcy-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J\u2019s Latest Bankruptcy Plan"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59731"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59731\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}